EXTON, Pa., Feb. 27, 2013 — /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the fourth quarter and year ended December 31, 2012.
In 2012, we:
•Achieved $428 million in annual net product sales, highlighted by $327 million in Worldwide net sales of Cinryze® (C1 esterase inhibitor [human]);
•Generated net sales of approximately $17 million in Europe
